Report Details:
15 Companies Covered
153 Pages
Market Highlights
The Influenza Diagnostics Market was valued at USD 1.94 Billion in 2025, and the market is projected to grow from USD 2.06 Billion in 2026 to USD 3.53 Billion by 2035, registering a CAGR of 6.15% during the forecast period 2026–2035.
Based on type of flu, the type A flu segment accounted for the largest market share in 2024, with a market value of USD 286.401 million. Influenza is a contagious respiratory infection caused by numerous flu viruses which affect the nose, throat, and lungs. As per the National Center for Biotechnology Information (NCBI) Report 2015, the influenza virus is responsible for seasonal epidemics affecting over 200,000 people with a death toll of approximately 30,000 to 50,000 patients every year in the US. As per the World Health Organization Report (WHO) 2024, influenza virus-infected 5% to 15% of the global population. As the prevalence of influenza is increasing, the number of diagnostic techniques such as immunochromatography-based rapid diagnostic test (RDT) and nucleic acid amplification test (NAAT) are used for the detection of influenza viruses in humans.
Segment Analysis
The global influenza diagnostics market is segmented into type of flu, test type, and end user. On the basis of type of flu, the global influenza diagnostics market is further sub-segmented as type A flu, type B flu, and type C flu. The type A flu accounted for the market value of USD 286.401 million in 2024.
By test type, the global influenza diagnostics market has been sub-segmented into traditional diagnostic tests and molecular diagnostic tests. The test type segment accounted for the larger market share in 2024. However, the type of flu segment is expected to exhibit higher CAGR during the forecast period. Based on end user, the global influenza diagnostics market has been sub-segmented into hospitals & clinical laboratories and point-of-care testing.
Influenza Diagnostics Market Regional Report Analysis
Geographically, the global influenza diagnostics market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. As per MRFR analysis, The Americas accounted for the largest market share of 38.0% in 2024, with a market value of USD 236.198 million, the market is expected to register a CAGR of 7.25% during the forecast period. Europe was the second-largest market in 2024. However, the market in Asia-Pacific is expected to register the highest CAGR.
Key Findings of the Study:
• By Test Type
- Rapid Influenza Diagnostic Tests captured 44.0% of the Influenza Diagnostics Market share in 2025, remaining the highest-volume test category despite lower sensitivity than molecular alternatives.
- CRISPR-based assays are projected to grow at a 10.0% CAGR through 2035, the fastest among all test type sub-segments.
- RT-PCR platforms accounted for USD 0.54 billion in 2025 revenue, underpinned by hospital laboratory procurement cycles.
• By End User
- Hospitals and Clinical Laboratories held 45.0% of the Influenza Diagnostics Market in 2025, reflecting centralized testing workflows.
- Point-of-care settings are forecast to expand at a 9.85% CAGR to 2035, supported by decentralized care models.
• By Geography
- North America commanded 40.0% of revenue in 2025, led by U.S. reimbursement clarity and laboratory density.
- Asia-Pacific is anticipated to grow at an 8.40% CAGR to 2035, the fastest among all regions.
Some of the players operating in the global influenza diagnostics market are Abbott, Analytik Jena AG, Becton, Dickinson and Company, Biocartis, bioMérieux Inc, Cepheid, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, GenMark Diagnostics, Inc., Luminex Corporation, Meridian Bioscience, Inc., Quidel Corporation, SA Scientific, Thermo Fisher Scientific Inc.
